Local Bone Graft vs BMP and Allograft

Local bone graft, BMP, and allograft all play important but different roles in spine fusion. Local bone is autologous material already present in the surgical field, allograft is donor bone used primarily as scaffold, and BMP is a recombinant biologic designed to stimulate bone formation rather than serve as a structural graft on its own.
 

Understanding the three options
 

Local bone is often considered the most efficient autologous source because it is harvested from the same operative exposure and can be reused immediately for fusion. It avoids the added morbidity of iliac crest harvest and keeps the graft strategy centered on tissue already generated during the case.

Allograft offers volume and availability without a separate patient harvest. AAOS explains that allograft generally serves as a scaffold on which the patient’s own bone can grow, rather than forming new bone on its own in the way autograft does. Review literature similarly describes allograft as abundant and useful, while noting concerns about slower incorporation, limited intrinsic biology compared with autograft, and small but real issues related to immunologic response and disease transmission.

BMP occupies a different category. Recombinant human BMPs, especially rhBMP-2, are osteoinductive proteins used to stimulate new bone formation and are commonly delivered on a carrier because the protein itself is not a structural graft. AAOS notes that synthetic BMP has been widely studied and is commonly used to improve fusion rates, although swelling risk limits use in some anatomic settings such as anterior cervical surgery.

What the evidence suggests

Across lumbar fusion studies, local autograft, allograft, and BMP-supported constructs have all achieved high fusion rates, but with different trade‑offs in biology and morbidity. Systematic reviews indicate that local autograft can provide fusion and clinical outcomes comparable to more traditional autograft strategies while avoiding a separate donor site, whereas allograft is primarily valuable as a structural scaffold or volume extender and relies on the host biology or added biologics to achieve similar results.

The literature on BMP is more nuanced. Some articles suggest that in lumbar interbody and posterolateral fusion settings, rhBMP‑2 that has demonstrated high fusion rates and can reduce or eliminate the need for supplemental autograft harvest, at the same time other review articles also describe concerns around cost, off‑label use, local soft‑tissue swelling, graft or cage subsidence in some constructs, and other product‑specific complications that have tempered long‑term enthusiasm.
 

Why local bone still matters
 

Even when BMP or allograft is used, local bone often remains clinically valuable. Reviews of graft options describe local autograft as a viable source that can be used alone in selected cases or combined with allograft, ceramics, or BMP-based strategies to increase volume and preserve autologous biology.

This is especially relevant in modern workflow-driven surgery. If usable local bone is already present in the field, preserving it can reduce dependence on additional graft products and help the surgeon build a layered strategy in which local bone provides biologic value while adjuncts add volume, structure, or osteoinductive signaling.
 

Deciding among them
 

Normally the surgeons’ choice depends on what the case actually needs. If the main need is autologous biology already available in the exposure, local bone may be sufficient; if the main need is volume, allograft or extenders may be added; if the main need is stronger osteoinductive drive in a higher-risk fusion environment, BMP may enter the discussion.

This framework is useful because it shifts the question away from brand or category alone and toward function: biology, scaffold, stimulation, volume, and workflow. In many procedures, the most efficient approach is not replacing local bone but preserving it and augmenting it only when the case truly requires more.
 

FAQ
 

Is BMP better than local bone?

BMP is not simply a better version of local bone. It serves a different purpose by providing strong osteoinductive signaling, often through a carrier (although many surgeons state that additional studies are required), whereas local bone provides autologous graft material already available in the field.

Analyses report that in certain lumbar fusion settings, rhBMP‑2 has been associated with similar fusion success at extended follow‑up compared with iliac crest autograft, but these gains must be weighed against a distinct complication profile and higher cost. Systematic safety reviews and registry data describe BMP‑associated issues such as radiculitis, vertebral osteolysis, ectopic bone formation, graft or cage subsidence, soft‑tissue swelling (particularly in anterior cervical uses), and hematoma, with complication rates reported from under 1% up to the low‑20% range depending on the region and approach.

Because of these trade‑offs, many authors still position autologous bone graft (iliac crest or local bone) as the reference standard for spine fusion, using BMP selectively when the perceived benefit justifies the additional risk and expense.
 

Is allograft the same as autograft?

No. Allograft primarily functions as an osteoconductive scaffold and does not replicate the full biologic profile of autograft, though it remains clinically useful in situations where autograft is not available or appropriate, including certain oncologic or structurally compromised cases.
 

Why use local bone if adjuncts are available?

Because local bone is autologous, already present, and potentially valuable, preserving it can improve efficiency and reduce waste even when adjuncts are used for added volume or biologic stimulation. It is also part of the autologous bone graft category that remains the gold standard for spinal fusion biology, since autograft (from iliac crest or local bone) uniquely provides living cells, osteoinductive factors, and an osteoconductive scaffold in a single graft source.
 

Disclaimer
 

This article is informational and does not make claims about the performance, safety, or effectiveness of any specific medical device, graft product, or surgical technique. Clinical decisions must be based on surgeon judgment, patient‑specific factors, and current regulatory‑cleared indications. Nothing in this document should be interpreted as promoting a device, altering standard of care, or suggesting superiority of one graft option over another.
 

Reference list
 

1. Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount. Nancy E Epstein  https://pmc.ncbi.nlm.nih.gov/articles/PMC3717531/

2. Bone grafts in spine surgery (AAOS patient education)
   http://www.orthoinfo.org/treatment/bone-grafts-in-spine-surgery/

3. Bone grafting options for lumbar spine surgery: review of clinical efficacy and complications
   (Bone Morphogenetic Protein / grafting options review)
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365636/

4. Synthetic bone graft materials in spine fusion: current evidence and future trends
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092933/

5. Synthetic bone graft versus autograft or allograft for spinal fusion: a systematic review
   http://www.pubmed.ncbi.nlm.nih.gov/27231812/

6. Iliac crest bone graft versus local autograft or allograft for lumbar spinal fusion: a systematic review
   http://www.journals.sagepub.com/doi/10.1055/s-0035-1570749

7. RIM Medical Technologies – Knowledge Centre (Bone graft recovery / workflow content hub)
   http://www.rimmedtech.com/knowledge-centre